{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T03:56:24Z","timestamp":1776052584604,"version":"3.50.1"},"reference-count":76,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,7,18]],"date-time":"2018-07-18T00:00:00Z","timestamp":1531872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","award":["KWF BUIT2010-4643"],"award-info":[{"award-number":["KWF BUIT2010-4643"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>To mount a strong anti-tumor immune response, non T cell inflamed (cold) tumors may require combination treatment encompassing vaccine strategies preceding checkpoint inhibition. In vivo targeted delivery of tumor-associated antigens (TAA) to dendritic cells (DCs), relying on the natural functions of primary DCs in situ, represents an attractive vaccination strategy. In this study we made use of a full-length MART-1 expressing C\/B-chimeric adenoviral vector, consisting of the Ad5 capsid and the Ad3 knob (Ad5\/3), which we previously showed to selectively transduce DCs in human skin and lymph nodes. Our data demonstrate that chimeric Ad5\/3 vectors encoding TAA, and able to target human DCs in situ, can be used to efficiently induce expansion of functional tumor-specific CD8+ effector T cells, either from a na\u00efve T cell pool or from previously primed T cells residing in the melanoma-draining sentinel lymph nodes (SLN). These data support the use of Ad3-knob containing viruses as vaccine vehicles for in vivo delivery. \u201cOff-the-shelf\u201d DC-targeted Ad vaccines encoding TAA could clearly benefit future immunotherapeutic approaches.<\/jats:p>","DOI":"10.3390\/vaccines6030042","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T03:50:43Z","timestamp":1531972243000},"page":"42","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Improved Induction of Anti-Melanoma T Cells by Adenovirus-5\/3 Fiber Modification to Target Human DCs"],"prefix":"10.3390","volume":"6","author":[{"given":"Dafni","family":"Chondronasiou","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy-Jane T. H. D.","family":"Eisden","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"},{"name":"Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, Amsterdam Infection & Immunity Institute, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita G. M.","family":"Stam","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiana L.","family":"Matthews","sequence":"additional","affiliation":[{"name":"Microbiology Program, Department of Biological Sciences, College of Science, Technology, Engineering and Mathematics, Alabama State University (ASU), Montgomery, AL 36104, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mert","family":"Icyuz","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Alabama in Birmingham (UAB), Birmingham, AL 35294, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Hooijberg","sequence":"additional","affiliation":[{"name":"Department of Pathology, Netherlands Cancer Institute\/Antoni van Leeuwenhoek, 1066 CX Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Dmitriev","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Washington University, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David T.","family":"Curiel","sequence":"additional","affiliation":[{"name":"Division of Cancer Biology, Washington University, St. Louis, MO 63110, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja D.","family":"De Gruijl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieneke","family":"Van de Ven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1479-5876-11-54","article-title":"The additional facet of immunoscore: Immunoprofiling as a possible predictive tool for cancer treatment","volume":"11","author":"Ascierto","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology Meets Immunology: The Cancer-Immunity Cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/CJI.0b013e31816a8910","article-title":"Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma","volume":"31","author":"Butterfield","year":"2008","journal-title":"J. Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nri1592","article-title":"Dendritic cells as therapeutic vaccines against cancer","volume":"5","author":"Banchereau","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/CJI.0b013e31817fd90b","article-title":"Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma","volume":"31","author":"Redman","year":"2008","journal-title":"J. Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1158\/1078-0432.CCR-08-2729","article-title":"Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients","volume":"15","author":"Verdijk","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00262-005-0106-6","article-title":"Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells","volume":"55","author":"Fay","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_13","first-page":"790","article-title":"Dendritic-cell immunotherapy: From ex vivo loading to in vivo targeting","volume":"7","author":"Tacken","year":"2007","journal-title":"Nat. Publ. Group"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.immuni.2008.08.001","article-title":"Dendritic cells in vivo: A key target for a new vaccine science","volume":"29","author":"Steinman","year":"2008","journal-title":"Immunity"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1158\/0008-5472.CAN-05-0938","article-title":"Targeting of antigens to activated dendritic cells in vivo cures metastatic melanoma in mice","volume":"65","author":"Mahnke","year":"2005","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/sj.gt.3302947","article-title":"Lentiviral vectors for cancer immunotherapy: Transforming infectious particles into therapeutics","volume":"14","author":"Breckpot","year":"2007","journal-title":"Gene Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ymeth.2006.05.027","article-title":"Liposomal vaccines\u2014Targeting the delivery of antigen","volume":"40","author":"Altin","year":"2006","journal-title":"Methods"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/156652311796150363","article-title":"Advances and future challenges in adenoviral vector pharmacology and targeting","volume":"11","author":"Khare","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/01.cji.0000211312.36363.56","article-title":"Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors","volume":"29","author":"Lotem","year":"2006","journal-title":"J. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/sj.gt.3301880","article-title":"Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: Implications for an efficient vaccination strategy","volume":"10","author":"Tuettenberg","year":"2003","journal-title":"Gene Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4049\/jimmunol.156.2.700","article-title":"Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy","volume":"156","author":"Zhai","year":"1996","journal-title":"J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.4049\/jimmunol.166.8.5236","article-title":"Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells","volume":"166","author":"Rea","year":"2001","journal-title":"J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1021\/mp050045c","article-title":"Genetic targeting strategies for adenovirus","volume":"2","author":"Noureddini","year":"2005","journal-title":"Mol. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ymthe.2004.03.010","article-title":"Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats","volume":"9","author":"Smith","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1084\/jem.182.1.261","article-title":"T cell priming versus T cell tolerance induced by synthetic peptides","volume":"182","author":"Aichele","year":"1995","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jgm.1565","article-title":"Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients","volume":"13","author":"Raki","year":"2011","journal-title":"J. Gene Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"11094","DOI":"10.1128\/JVI.77.20.11094-11104.2003","article-title":"General strategy for broadening adenovirus tropism","volume":"77","author":"Fontana","year":"2003","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.virol.2004.02.016","article-title":"Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors","volume":"322","author":"Short","year":"2004","journal-title":"Virology"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/CJI.0b013e3181b56deb","article-title":"Selective transduction of mature DC in human skin and lymph nodes by CD80\/CD86-targeted fiber-modified adenovirus-5\/3","volume":"32","author":"Lindenberg","year":"2009","journal-title":"J. Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/modpathol.3880358","article-title":"Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: Implications for tumor biology and treatment","volume":"14","author":"Cochran","year":"2001","journal-title":"Mod. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nri1919","article-title":"Tumour-induced immune modulation of sentinel lymph nodes","volume":"6","author":"Cochran","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/B978-0-12-398342-8.00006-9","article-title":"Chapter six\u2014Adenovirus-based immunotherapy of cancer: Promises to keep","volume":"115","year":"2012","journal-title":"Adv. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1128\/CVI.00311-10","article-title":"The Th1 immune response to Plasmodium falciparum circumsporozoite protein is boosted by adenovirus vectors 35 and 26 with a homologous insert","volume":"17","author":"Rodriguez","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6226","DOI":"10.1016\/j.vaccine.2009.07.106","article-title":"Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys","volume":"27","author":"Rodriguez","year":"2009","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1016\/j.vaccine.2010.06.050","article-title":"Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28","volume":"28","author":"Kahl","year":"2010","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-07-4711","article-title":"Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients","volume":"14","author":"Molenkamp","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1006\/cimm.1999.1520","article-title":"Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells","volume":"195","author":"Heemskerk","year":"1999","journal-title":"Cell. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.4049\/jimmunol.171.6.2912","article-title":"In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones","volume":"171","author":"Schreurs","year":"2003","journal-title":"J. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/CJI.0b013e3181eccbd4","article-title":"Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus","volume":"33","author":"Hangalapura","year":"2010","journal-title":"J. Immunother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0022-1759(84)90450-2","article-title":"Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones","volume":"72","author":"Yssel","year":"1984","journal-title":"J. Immunol. Methods"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood-2011-03-344838","article-title":"Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation","volume":"118","author":"Lindenberg","year":"2011","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.4049\/jimmunol.180.7.4540","article-title":"Inducing antitumor T cell immunity: Comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model","volume":"180","author":"Santegoets","year":"2008","journal-title":"J. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1634\/theoncologist.2012-0391","article-title":"Ipilimumab, vemurafenib, dabrafenib, and trametinib: Synergistic competitors in the clinical management of BRAF mutant malignant melanoma","volume":"18","author":"Luke","year":"2013","journal-title":"Oncologist"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Van der Burg, S.H. (2018). Correlates of immune and clinical activity of novel cancer vaccines. Semin. Immunol.","DOI":"10.1016\/j.smim.2018.04.001"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-3-319-67577-0_3","article-title":"Regulation of CTL Infiltration within the Tumor Microenvironment","volume":"1036","author":"Church","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_46","first-page":"5850","article-title":"Heterogeneous T-cell response to MAGE-A10(254-262): High avidity-specific cytolytic T lymphocytes show superior antitumor activity","volume":"61","author":"Dutoit","year":"2001","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7855","DOI":"10.1073\/pnas.93.15.7855","article-title":"Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction","volume":"93","author":"Toes","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0b013e318233e5b2","article-title":"The present and future of peptide vaccines for cancer: Single or multiple, long or short, alone or in combination?","volume":"17","author":"Slingluff","year":"2011","journal-title":"Cancer J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1089\/10430340050015653","article-title":"Adenovirus vector-mediated gene transfer to regional lymph nodes","volume":"11","author":"Labow","year":"2000","journal-title":"Hum. Gene Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1128\/JVI.74.16.7678-7682.2000","article-title":"Immune response to recombinant adenovirus in humans: Capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes","volume":"74","author":"Ribault","year":"2000","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1089\/10430349950016555","article-title":"Cellular immune responses of healthy individuals to intradermal administration of an E1-E3-adenovirus gene transfer vector","volume":"10","author":"Harvey","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","article-title":"International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations","volume":"29","author":"Barouch","year":"2011","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0042-6822(03)00161-2","article-title":"Development of adenovirus serotype 35 as a gene transfer vector","volume":"311","author":"Ganesh","year":"2003","journal-title":"Virology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3390\/v2092134","article-title":"An update on canine adenovirus type 2 and its vectors","volume":"2","author":"Bru","year":"2010","journal-title":"Viruses"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"6594","DOI":"10.1128\/JVI.02497-06","article-title":"Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors","volume":"81","author":"McCoy","year":"2007","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/sj.gt.3302588","article-title":"A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy","volume":"12","author":"Rivera","year":"2005","journal-title":"Gene Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","article-title":"Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D","volume":"81","author":"Abbink","year":"2007","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.4049\/jimmunol.177.4.2208","article-title":"Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells","volume":"177","author":"Ophorst","year":"2006","journal-title":"J. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1158\/0008-5472.CAN-11-0804","article-title":"Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine","volume":"71","author":"Hangalapura","year":"2011","journal-title":"Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.32607\/20758251-2014-6-4-27-39","article-title":"Regulation of the target protein (transgene) expression in the adenovirus vector using agonists of toll-like receptors","volume":"6","author":"Bagaev","year":"2014","journal-title":"Acta Nat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.4049\/jimmunol.1400197","article-title":"Priming of CD8 T cells by adenoviral vectors is critically dependent on B7 and dendritic cells but only partially dependent on CD28 ligation on CD8 T cells","volume":"193","author":"Nielsen","year":"2014","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00432-014-1606-6","article-title":"Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity","volume":"140","author":"Zhang","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CJI.0000000000000028","article-title":"A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells","volume":"37","author":"Liljenfeldt","year":"2014","journal-title":"J. Immunother."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/jgm.1648","article-title":"CD40-targeted adenoviral cancer vaccines: The long and winding road to the clinic","volume":"14","author":"Hangalapura","year":"2012","journal-title":"J. Gene Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1016\/j.vaccine.2004.02.011","article-title":"An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity","volume":"22","author":"Ophorst","year":"2004","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7179","DOI":"10.4049\/jimmunol.174.11.7179","article-title":"Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein","volume":"174","author":"Sumida","year":"2005","journal-title":"J. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature04721","article-title":"Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity","volume":"441","author":"Roberts","year":"2006","journal-title":"Nature"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1093\/infdis\/jiu217","article-title":"First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)","volume":"210","author":"Baden","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2174\/1874357901610010010","article-title":"Development of an Ad5H3 Chimera Using the \u201cAntigen Capsid-Incorporation\u201d Strategy for an Alternative Vaccination Approach","volume":"10","author":"Gu","year":"2016","journal-title":"Open Virol. J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/156652307781369137","article-title":"Adenovirus vectors composed of subgroup B adenoviruses","volume":"7","author":"Sakurai","year":"2007","journal-title":"Curr. Gene Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.immuni.2010.10.004","article-title":"Immunologic basis of vaccine vectors","volume":"33","author":"Liu","year":"2010","journal-title":"Immunity"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Wang, H., Li, Z.-Y., Liu, Y., Persson, J., Beyer, I., ller, T.M.O., Koyuncu, D., Drescher, M.R., Strauss, R., and Zhang, X.-B. (2010). Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med., 1\u201310.","DOI":"10.1038\/nm.2270"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jim.2004.04.025","article-title":"Successful live cell harvest from bisected sentinel lymph nodes research report","volume":"291","author":"Elliott","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2016.1265717","article-title":"Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy","volume":"6","author":"Zafar","year":"2017","journal-title":"Oncoimmunology"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/3\/42\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:12:53Z","timestamp":1760195573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/3\/42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,18]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["vaccines6030042"],"URL":"https:\/\/doi.org\/10.3390\/vaccines6030042","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,18]]}}}